Chapter 38 : Cryptococcosis in AIDS

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Cryptococcosis in AIDS, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816858/9781555815011_Chap38-1.gif /docserver/preview/fulltext/10.1128/9781555816858/9781555815011_Chap38-2.gif


Infection with HIV is the most common predisposing condition for developing cryptococcosis. This chapter focuses on aspects that are specific to the coinfection of HIV and . These include clinical presentation, treatment regimens, alterations of the host immune response, and concerns about drug toxicities and interactions. Soon after the HIV pandemic was recognized in the United States and Europe, it became clear that cryptococcosis was an important opportunistic pathogen in patients with AIDS. infection in AIDS patients can either be the result of a newly acquired primary infection or alternatively constitute a reactivation of latent infection. Patients with AIDS who respond to highly active antiretroviral therapy (HAART) show a greatly reduced incidence of opportunistic infections such as cryptococcosis. Experimental evidence suggests that coinfection can affect HIV replication. Another factor that may affect HIV-infected patients’ ability to mount a successful antifungal host response is the common abuse of methamphetamine. This drug exposure facilitates intracellular replication and inhibits intracellular killing of and thus affects pathogenesis in these patients. The most common manifestation of cryptococcosis in patients with HIV infection is meningoencephalitis, and central nervous system (CNS) involvement is found in the vast majority of patients with AIDS in whom cryptococcal infection is diagnosed. The treatment of AIDS-associated cryptococcal meningitis is usually divided into three stages: induction, consolidation, and maintenance.

Citation: Fries B, Cox G. 2011. Cryptococcosis in AIDS, p 515-525. In Heitman J, Kozel T, Kwon-Chung K, Perfect J, Casadevall A (ed), . ASM Press, Washington, DC. doi: 10.1128/9781555816858.ch38
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of FIGURE 1

Effect of indinavir on Kinetics of IFN-γ and IL-2 production from splenocytes of mice treated with indinavir and challenged with Cells were cultured for 18 h in the presence of heat-inactivated (E:T = 1:2), and supernatants were tested for (A) IFN-γ and (B) IL-2 levels by specific enzyme-linked immunosorbent assays. In selected experiments, 5 days after infection, unfractionated splenocytes were cultured as above, CD3 T cells were subsequently purified, and intracellular staining for (C) IFN-γ and (D) IL-2 was evaluated. Data reported are mean ± SE from three separate experiments; *, < 0.05 (indinavir + versus (e) CFU recovery from the brain was determined 3, 5, 10, 15, and 20 days after fungal infection; indinavir (25 or 10 μmol/0.2 ml, days 3, 2, 1). Data reported are mean ± SE from five separate experiments; *, < 0.05 (indinavir-treated versus (f) Histological analysis of brains from mice treated with indinavir. Mice were treated with indinavir (10 μmol/0.2 ml, days 3, 2, 1) and subsequently infected with Ten days after infection, animals were killed, brains were excised, and brain sections were stained with periodic acid-Schiff stain. (f–A, f–B) Brain sections from mice infected with (f–C, f–D) Brain sections from mice treated with indinavir and infected with Original magnification, x2.5 (f–A, f–C); x40 (f–B, f–D) ( ).

Citation: Fries B, Cox G. 2011. Cryptococcosis in AIDS, p 515-525. In Heitman J, Kozel T, Kwon-Chung K, Perfect J, Casadevall A (ed), . ASM Press, Washington, DC. doi: 10.1128/9781555816858.ch38
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2

Methamphetamine (Meth) and chloroquine (Clq) inhibit phagocytosis of fungi. (A) Cells were incubated in Meth or Clq for 2 h, and then immunoglobulin G (IgG)-coated erythrocytes were added. Extracellular uningested IgG-coated erythrocytes were lysed and removed. Phagocytic index was quantified and inhi bition is indicated as percentage of control. Data were collected from four to seven experiments ( = 300 cells; mean ± SEM; ***, < 0.0001, two-tailed ANOVA). (B) Images of macrophage cells impaired in the phagocytosis of opsonized sheep erythrocytes after 2 h of Meth or Clq treatment. Arrows denote phagocytosed erythrocytes. Scale bar, 10 μm. (C, D) J774.16 cells were exposed to phosphate-buffered saline, Clq, or Meth for 2 h followed by incubation with or The phagocytic indices were determined after 1 h or 30 min for and , respectively (C). (Statistics: = 300; mean ± SEM; *, < 0.05, two-tailed ANOVA.) CFU after 24 h incubations (D). ( = 300 cells; mean ± SEM; *, < 0.05, two-tailed ANOVA.) From reference .

Citation: Fries B, Cox G. 2011. Cryptococcosis in AIDS, p 515-525. In Heitman J, Kozel T, Kwon-Chung K, Perfect J, Casadevall A (ed), . ASM Press, Washington, DC. doi: 10.1128/9781555816858.ch38
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Abadi, J., and, L. Pirofski. 1999. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection. J. Infect. Dis. 180: 915919.
2. Abou-Gabal, M., and, M. Atia. 1978. Study of the role of pigeons in the dissemination of Cryptococcus neoformans in nature. Sabouraudia 16: 6368.
3. Abu-Raddad, L. J., P. Patnaik, and, J. G. Kublin. 2006. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science 314: 16031606.
4. Asawavichienjinda, T.,, C. Sitthi-Amorn, and, V. Tanyanont. 1999. Serum cryptococcal antigen: diagnostic value in the diagnosis of AIDS-related cryptococcal meningitis. J. Med. Assoc. Thailand 82: 6571.
5. Bicanic,, T.,, G. Meintjes,, R. Wood,, M. Hayes,, K. Rebe,, L. G. Bekker, and T. Harrison. 2007. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviralnaive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin. Infect. Dis. 45: 7680.
6. Brouwer,, A. E.,, P. Teparrukkul,, S. Pinpraphaporn,, R. A. Larsen,, W. Chierakul,, S. Peacock,, N. Day,, N. J. White, and, T. S. Harrison. 2005. Baseline correlation and comparative kinetics of cerebrospinal fluid colony-forming unit counts and antigen titers in cryptococcal meningitis. J. Infect. Dis. 192: 681684.
7. Casolari,, C.,, T. Rossi,, G. Baggio,, A. Coppi,, G. Zandomeneghi,, A. I. Ruberto,, C. Farina,, G. Fabio,, A. Zanca, and M. Castelli. 2004. Interaction between saquinavir and antimycotic drugs on C. albicans and C. neoformans strains. Pharmacol. Res. 50: 605610.
8. Castella, G.,, M. L. Abarca, and, F. J. Cabanes. 2008. Cryptococcosis and pets. Rev. Iberoam. Micol. 25: S19S24 (In Spanish.).
9. Cauda,, R.,, E. Tacconelli,, M. Tumbarello,, G. Morace,, F. De Bernardis,, A. Torosantucci, and A. Cassone. 1999. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J. Acquir. Immune Defic. Syndr. 21: 2025.
10. Cenci,, E.,, D. Francisci,, B. Belfiori,, S. Pierucci,, F. Baldelli,, F. Bistoni, and A. Vecchiarelli. 2008. Tipranavir exhibits different effects on opportunistic pathogenic fungi. J. Infect. 56: 5864.
11. Chanock, S.,, P. Toltzis, and, C. Wilson. 1993. Cross-reactivity between Stomatococcus mucilaginosus and latex agglutination for cryptococcal antigen. Lancet 342: 11191120.
12. Charlier,, C.,, F. Dromer,, C. Leveque,, L. Chartier,, Y. S. Cordoliani,, A. Fontanet,, O. Launay,, O. Ortholary, and the French Cryptococcosis Study Group. 2008. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS ONE 3: E1950.
13. Charlier,, C.,, K. Nielsen,, S. Daou,, M. Brigitte,, F. Chretien, and F. Dromer. 2009. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect. Immun. 77: 120127.
14. Chen,, S.,, T. Sorrell,, G. Nimmo,, B. Speed,, B. Currie,, D. Ellis,, D. Marriott,, T. Pfeiffer,, D. Parr, and K. Byth. 2000. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin. Infect. Dis. 31: 499508.
15. Cressey, T. R.,, N. Plipat,, F. Fregonese, and, K. Chokephaibulkit. 2007. Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings. Expert Opin. Drug Metab. Toxicol. 3: 347361.
16. Currie,, B.,, H. Sanati,, A. S. Ibrahim,, J. E. Edwards, Jr.,, A. Casadevall, and, M. A. Ghannoum. 1995. Sterol compositions and susceptibilities to amphotericin B of environmental Cryptococcus neoformans isolates are changed by murine passage. Antimicrob. Agents Chemother. 39: 19341937.
17. Currie, B. P., and, A. Casadevall. 1994. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin. Infect. Dis. 19: 10291033.
18. Currie, B. P.,, L. F. Freundlich, and, A. Casadevall. 1994. Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical sources in New York City. J. Clin. Microbiol. 32: 11881192.
19. Darras-Joly,, C.,, S. Chevret,, M. Wolff,, S. Matheron,, P. Longuet,, E. Casalino,, V. Joly,, C. Chochillon, and J. Bedos. 1996. Cryptococcus neoformans infection in France: epidemiologic features of and early prognostic parameters for 76 patients who were infected with human immunodeficiency virus. Clin. Infect. Dis. 23: 369376.
20. Dorrington, R.,, D. Bourne,, D. Bradshaw,, R. Laubscher, and, I. Timaeus. 2001. The impact of HIV/AIDS on adult mortality in South Africa. Technical report for the South African Medical Research Council.
21. Dromer, F.,, S. Mathoulin,, B. Dupont, and, A. Laporte. 1996. Epidemiology of cryptococcosis in France: a 9-year survey (1985–1993). French Cryptococcosis Study Group. Clin. Infect. Dis. 23: 8290.
22. Dromer,, F.,, S. Mathoulin-Pelissier,, A. Fontanet,, O. Ronin,, B. Dupont, and O. Lortholary for the French Cryptococcosis Study Group. 2004. Epidemiology of HIV-associated cryptococcosis in France (1985–2001): comparison of the pre- and post-HAART eras. AIDS 18: 555562.
23. Dromer, F.,, S. Mathoulin-Pelissier,, O. Launay,, O. Lortholary, and the French Cryptococcosis Study Group. 2007. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 4: E21.
24. Dromer, F.,, O. Ronin, and, B. Dupont. 1992. Isolation of Cryptococcus neoformans var. gattii from an Asian patient in France: evidence for dormant infection in healthy subjects. J. Med. Vet. Mycol. 30: 395397.
25. Ellis, D. H. 1987. Cryptococcus neoformans var. gattii in Australia. J. Clin. Microbiol. 25: 430431.
26. Fan-Havard, P.,, E. Yamaguchi,, S. Smith, and, R. Eng. 1992. Diastolic hypertension in AIDS patients with cryptococcal meningitis. Am. J. Med. 93: 347.
27. Feldmesser, M.,, Y. Kress,, P. Novikoff, and, A. Casadevall. 2000. Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect. Immun. 68: 42254237.
28. Franzot,, S. P.,, J. S. Hamdan,, B. P. Currie, and A. Casadevall. 1997. Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure. J. Clin. Microbiol. 35: 22432251.
29. Franzot,, S. P.,, J. Mukherjee,, R. Cherniak,, L. C. Chen,, J. S. Hamdan, and A. Casadevall. 1998. Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect. Immun. 66: 8997.
30. Fries, B. C., and, A. Casadevall. 1998. Serial isolates of Cryptococcus neoformans from patients with AIDS differ in virulence for mice. J. Infect. Dis. 178: 17611766.
31. Fries, B. C.,, E. Cook,, X. Wang, and, A. Casadevall. 2005. Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans. Antimicrob. Agents Chemother. 49: 350357.
32. Garcia-Hermoso, D.,, G. Janbon, and, F. Dromer. 1999. Epidemiological evidence for dormant Cryptococcus neoformans infection. J. Clin. Microbiol. 37: 32043209.
33. Garcia-Hermoso,, D.,, S. Mathoulin-Pelissier,, B. Couprie,, O. Ronin,, B. Dupont, and F. Dromer. 1997. DNA typing suggests pigeon droppings as a source of pathogenic Cryptococcus neoformans serotype D. J. Clin. Microbiol. 35: 26832685.
34. Goldman, D.,, S. C. Lee, and, A. Casadevall. 1994. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect. Immun. 62: 47554761.
35. Gordon,, S. B.,, A. L. Walsh,, M. Chaponda,, M. A. Gordon,, D. Soko,, M. Mbwvinji,, M. E. Molyneux, and, R. C. Read. 2000. Bacterial meningitis in Malawian adults: pneumococcal disease is common, severe, and seasonal. Clin. Infect. Dis. 31: 5357.
36. Goulder, P. J., and, D. I. Watkins. 2008. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat. Rev. Immunol. 8: 619630.
37. Graybill,, J. R.,, J. Sobel,, M. Saag,, C. van Der Horst,, W. Powderly,, G. Cloud,, L. Riser,, R. Hamill, and W. Dismukes. 2000. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin. Infect. Dis. 30: 4754.
38. Hajjeh,, R. A.,, L. A. Conn,, D. S. Stephens,, W. Baughman,, R. Hamill,, E. Graviss,, P. G. Pappas,, C. Thomas,, A. Reingold,, G. Rothrock,, L. C. Hutwagner,, A. Schuchat,, M. E. Brandt, and, R. W. Pinner. 1999. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J. Infect. Dis. 179: 449454.
39. Harrison, T. S., and, S. M. Levitz. 1997. Mechanisms of impaired anticryptococcal activity of monocytes from donors infected with human immunodeficiency virus. J. Infect. Dis. 176: 537540.
40. Harrison, T. S.,, S. Nong, and, S. M. Levitz. 1997. Induction of human immunodeficiency virus type 1 expression in monocytic cells by Cryptococcus neoformans and Candida albicans. J. Infect. Dis. 176: 485491.
41. Ieong,, M. H.,, C. C. Reardon,, S. M. Levitz, and H. Kornfeld. 2000. Human immunodeficiency virus type 1 infection of alveolar macrophages impairs their innate fungicidal activity. Am. J. Respir. Crit. Care Med. 162: 966970.
42. Jain,, N.,, B. L. Wickes,, S. M. Keller,, J. Fu,, A. Casadevall,, P. Jain,, M. A. Ragan,, U. Banerjee, and, B. C. Fries. 2005. Molecular epidemiology of clinical Cryptococcus neoformans strains from India. J. Clin. Microbiol. 43: 57335742.
43. Jarvis,, J. N.,, S. D. Lawn,, M. Vogt,, N. Bangani,, R. Wood, and, T. S. Harrison. 2009. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin. Infect. Dis. 48: 856862.
44. Kaur,, A.,, N. Kassis,, C. L. Hale,, M. Simon,, M. Elliott,, A. Gomez-Yafal,, J. D. Lifson,, R. C. Desrosiers,, F. Wang,, P. Barry,, M. Mach, and, R. P. Johnson. 2003. Direct relationship between suppression of virus-specific immunity and emergence of cytomegalovirus disease in simian AIDS. J. Virol. 77: 57495758.
45. Lee, S. C.,, A. Casadevall, and, D. W. Dickson. 1996. Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis. Am. J. Pathol. 148: 12671274.
46. Liappis,, A. P.,, V. L. Kan,, N. C. Richman,, B. Yoon,, B. Wong, and, G. L. Simon. 2008. Mannitol and inflammatory markers in the cerebral spinal fluid of HIV-infected patients with cryptococcal meningitis. Eur. J. Clin. Microbiol. Infect. Dis. 27: 477479.
47. Litvintseva, A. P.,, L. Kestenbaum,, R. Vilgalys, and, T. G. Mitchell. 2005. Comparative analysis of environmental and clinical populations of Cryptococcus neoformans. J. Clin. Microbiol. 43: 556564.
48. Litvintseva,, A. P.,, X. Lin,, I. Templeton,, J. Heitman, and, T. G. Mitchell. 2007. Many globally isolated AD hybrid strains of Cryptococcus neoformans originated in Africa. PLoS Pathog. 3: E114.
49. Lortholary,, O.,, F. Dromer,, S. Mathoulin-Pelissier,, C. Fitting,, L. Improvisi,, J. M. Cavaillon,, B. Dupont, and the French Cryptococcosis Study Group. 2001. Immune mediators in cerebrospinal fluid during cryptococcosis are influenced by meningeal involvement and human immunodeficiency virus serostatus. J. Infect. Dis. 183: 294302.
50. McCarthy, K.,, H. H. Crewe-Brown,, M. R. B. Maloba, and, R. Hajjeh. 2003. The burden of cryptococcosis in Gauteng: results of population-based active surveillance: 2002–2003. Comm. Dis. Surv. Bull. Nov.: 1012.
51. McManus, E., and, J. Jones. 1985. Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharides in serum from a patient with disseminated Trichosporon infection. J. Clin. Microbiol. 21: 681.
52. Micol,, R.,, O. Lortholary,, B. Sar,, D. Laureillard,, C. Ngeth,, J. -P. Dousset,, H. Chanroeun,, L. Ferradini,, P. J. Guerin,, F. Dromer, and A. Fontanet. 2007. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J. Acquir. Immune Defic. Syndr. 45: 555559.
53. Mirza,, S. A.,, M. Phelan,, D. Rimland,, E. Graviss,, R. Hamill,, M. E. Brandt,, T. Gardner,, M. Sattah,, G. P. de Leon,, W. Baughman, and, R. A. Hajjeh. 2003. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992–2000. Clin. Infect. Dis. 36: 789794.
54. Mitchell, T., and, J. Perfect. 1995. Cryptococcosis in the era of AIDS: 100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8: 515548.
55. Molez, J.-F. 1998. The historical question of acquired immunodeficiency syndrome in the 1960s in the Congo River Basin area in relation to cryptococcal meningitis. Am. J. Trop. Med. Hyg. 58: 273276.
56. Monari, C.,, A. Casadevall,, D. Pietrella,, F. Bistoni, and, A. Vecchiarelli. 1999. Neutrophils from patients with advanced human immunodeficiency virus infection have impaired complement receptor function and preserved Fcgamma receptor function. J. Infect. Dis. 180: 15421549.
57. Monari,, C.,, E. Pericolini,, G. Bistoni,, E. Cenci,, F. Bistoni, and A. Vecchiarelli. 2005. Influence of indinavir on virulence and growth of Cryptococcus neoformans. J. Infect. Dis. 191: 307311.
58. Moore, R. D. 2000. Cost effectiveness of combination HIV therapy: 3 years later. Pharmacoeconomics 17: 325330.
59. Morgan,, J.,, K. M. McCarthy,, S. Gould,, K. Fan,, B. Arthington-Skaggs,, N. Iqbal,, K. Stamey,, R. A. Hajjeh, and, M. E. Brandt. 2006. Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002–2004. Clin. Infect. Dis. 43: 10771080.
60. Morris,, L.,, E. Silber,, P. Sonnenberg,, S. Eintracht,, S. Nyoka,, S. F. Lyons,, D. Saffer,, H. Koornhof, and, D. J. Martin. 1998. High human immunodeficiency virus type 1 RNA load in the cerebrospinal fluid from patients with lymphocytic meningitis. J. Infect. Dis. 177: 473476.
61. Mussini, C.,, P. Pezzotti, and, J. Miro. 2004. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin. Infect. Dis. 38: 565.
62. Nosanchuk,, J. D.,, S. Shoham,, B. C. Fries,, D. S. Shapiro,, S. M. Levitz, and A. Casadevall. 2000. Evidence of zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann. Intern. Med. 132: 205208.
63. Orendi,, J. M.,, H. S. Nottet,, M. R. Visser,, A. F. Verheul,, H. Snippe, and J. Verhoef. 1994. Enhancement of HIV-1 replication in peripheral blood mononuclear cells by Cryptococcus neoformans is monocyte-dependent but tumour necrosis factor-independent. AIDS 8: 423429.
64. Paiardini, M.,, I. Frank,, I. Pandrea,, C. Apetrei, and, G. Silvestri. 2008. Mucosal immune dysfunction in AIDS pathogenesis. AIDS Rev. 10: 3646.
65. Pappas,, P. G.,, B. Bustamante,, E. Ticona,, R. J. Hamill,, P. C. Johnson,, A. Reboli,, J. Aberg,, R. Hasbun, and, H. H. Hsu. 2004. Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J. Infect. Dis. 189: 2185.
66. Pappas,, P. G.,, P. Chetchotisakd,, R. A. Larsen,, W. Manosuthi,, M. I. Morris,, T. Anekthananon,, S. Sungkanuparph,, K. Supparatpinyo,, T. L. Nolen,, L. O. Zimmer,, A. S. Kendrick,, P. Johnson,, J. D. Sobel, and, S. G. Filler. 2009. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin. Infect. Dis. 48: 17751783.
67. Park,, B. J.,, K. A. Wannemuehler,, B. J. Marston,, N. Govender,, P. G. Pappas, and, T. M. Chiller. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525530.
68. Pericolini,, E.,, E. Cenci,, E. Gabrielli,, S. Perito,, P. Mosci,, F. Bistoni, and A. Vecchiarelli. 2008. Indinavir influences biological function of dendritic cells and stimulates antifungal immunity. J. Leukoc. Biol. 83: 12861294.
69. Pericolini,, E.,, E. Cenci,, C. Monari,, M. De Jesus,, F. Bistoni,, A. Casadevall, and A. Vecchiarelli. 2006. Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8. Cell. Microbiol. 8: 267275.
70. Pericolini,, E.,, E. Cenci,, C. Monari,, S. Perito,, P. Mosci,, G. Bistoni, and A. Vecchiarelli. 2006. Indinavir-treated Cryptococcus neoformans promotes an efficient antifungal immune response in immunosuppressed hosts. Med. Mycol. 44: 119126.
71. Pettoello-Mantovani, M.,, A. Casadevall, and, H. Goldstein. 1993. The presence of cryptococcal capsular polysaccharide increases the sensitivity of HIV-1 coculture in children. Ann. NY Acad. Sci. 693: 281283.
72. Pettoello-Mantovani,, M.,, A. Casadevall,, T. R. Kollmann,, A. Rubinstein, and H. Goldstein. 1992. Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet 339: 2123.
73. Pettoello-Mantovani, M.,, A. Casadevall,, P. Smarnworawong, and, H. Goldstein. 1994. Enhancement of HIV type 1 infectivity in vitro by capsular polysaccharide of Cryptococcus neoformans and Haemophilus influenzae. AIDS Res. Hum. Retrovir. 10: 10791087.
74. Robinson,, P. A.,, M. Bauer,, M. A. E. Leal,, S. G. Evans,, P. D. Holton,, D. M. Diamond,, J. M. Leedom, and, R. A. Larsen. 1999. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. 28: 8292.
75. Saag,, M. S.,, R. J. Graybill,, R. A. Larsen,, P. G. Pappas,, J. R. Perfect,, W. G. Powderly,, J. D. Sobel, and, W. E. Dismukes. 2000. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. 30: 710718.
76. Saag,, M. S.,, W. G. Powderly,, G. A. Cloud,, P. Robinson,, M. H. Grieco,, P. K. Sharkey,, S. E. Thompson,, A. M. Sugar,, C. U. Tuazon,, J. F. Fisher,, N. Hyslop,, J. M. Jacobson,, R. Hafner, and, W. E. Dismukes. 1992. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N. Engl. J. Med. 326: 8389.
77. Saha,, D. C.,, D. L. Goldman,, X. Shao,, A. Casadevall,, S. Husain,, A. P. Limaye,, M. Lyon,, J. Somani,, K. Pursell,, T. L. Pruett, and N. Singh. 2007. Serologic evidence for reactivation of cryptococcosis in solid-organ transplant recipients. Clin. Vaccine Immunol. 14: 15501554.
78. Sahai, J.,, K. Gallicano,, A. Pakuts, and, D. Cameron. 1994. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J. Infect. Dis. 169: 11031107.
79. Talloczy,, Z.,, J. Martinez,, D. Joset,, Y. Ray,, A. Gacser,, S. Toussi,, N. Mizushima,, J. Nosanchuk,, H. Goldstein,, J. Loike,, D. Sulzer, and L. Santambrogio. 2008. Methamphetamine inhibits antigen processing, presentation, and phagocytosis. PLoS Pathog. 4: E28.
80. Tanner,, D.,, M. Weinstein,, B. Fedorciw,, K. Joho,, J. Thorpe, and L. Reller. 1994. Comparison of commercial kits for detection of cryptococcal antigen. J. Clin. Microbiol. 32: 16801684.
81. Toborek,, M.,, Y. W. Lee,, G. Flora,, H. Pu,, I. E. Andras,, E. Wylegala,, B. Hennig, and A. Nath. 2005. Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell. Mol. Neurobiol. 25: 181199.
82. van der Horst,, C. M.,, M. S. Saag,, G. A. Cloud,, R. J. Hamill,, J. R. Graybill,, J. D. Sobel,, P. C. Johnson,, C. U. Tuazon,, T. Kerkering,, B. L. Moskovitz,, W. G. Powderly, and, W. E. Dismukes. 1997. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N. Engl. J. Med. 337: 1521.
83. Viviani,, M. A.,, M. Cogliati,, M. C. Esposto,, K. Lemmer,, K. Tintelnot,, M. F. Colom Valiente,, D. Swinne,, A. Velegraki, and R. Velho. 2006. Molecular analysis of 311 Cryptococcus neoformans isolates from a 30-month ECMM survey of cryptococcosis in Europe. FEMS Yeast Res. 6: 614619.
84. Vullo, V.,, C. M. Mastroianni,, M. Lichtner,, F. Mengoni, and, S. Delia. 1995. Increased cerebrospinal fluid levels of soluble receptors for tumour necrosis factor in HIV-infected patients with neurological diseases. AIDS 9: 10991100.
85. Wagner,, R. P.,, S. M. Levitz,, A. Tabuni, and H. Kornfeld. 1992. HIV-1 envelope protein (gp120) inhibits the activity of human bronchoalveolar macrophages against Cryptococcus neoformans. Am. Rev. Respir. Dis. 146: 14341438.
86. Westerink, M.,, D. Amsterdam, and, R. Petell. 1987. Septicemia due to DF-2. Cause of a false-positive cryptococcal latex agglutination result. Am. J. Med. 83: 155.
87. Wickes,, B. L.,, M. E. Mayorga,, U. Edman, and, J. C. Edman. 1996. Dimorphism and haploid fruiting in Cryptococcus neoformans: association with the alphamating type. Proc. Natl. Acad. Sci. USA 93: 73277331.
88. Wyles, D. L. 2008. Hepatitis virus coinfection in the Strategic Management of Antiretroviral Therapy (SMART) study: a marker for nonliver, non-opportunistic disease mortality. Clin. Infect. Dis. 47: 14761478.
89. Zheng,, C. F.,, G. J. Jones,, M. Shi,, J. C. Wiseman,, K. J. Marr,, B. M. Berenger,, S. M. Huston,, M. J. Gill,, A. M. Krensky,, P. Kubes, and, C. H. Mody. 2008. Late expression of granulysin by microbicidal CD4+ T cells requires PI3K-and STAT5-dependent expression of IL-2Rbeta that is defective in HIV-infected patients. J. Immunol. 180: 72217229.


Generic image for table

Characteristics of 575 patients presenting with AIDS-associated cryptococcal meningitis in two large treatment trials from 1988 to 1994

Citation: Fries B, Cox G. 2011. Cryptococcosis in AIDS, p 515-525. In Heitman J, Kozel T, Kwon-Chung K, Perfect J, Casadevall A (ed), . ASM Press, Washington, DC. doi: 10.1128/9781555816858.ch38

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error